Asset Management One Co. Ltd. Sells 2,328 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Asset Management One Co. Ltd. lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 68,749 shares of the medical research company’s stock after selling 2,328 shares during the period. Asset Management One Co. Ltd.’s holdings in IQVIA were worth $13,708,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the stock. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA in the 3rd quarter valued at approximately $27,000. Synergy Asset Management LLC acquired a new stake in IQVIA in the fourth quarter valued at $33,000. Avior Wealth Management LLC grew its holdings in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the period. Assetmark Inc. raised its stake in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after buying an additional 196 shares during the period. Finally, Concord Wealth Partners acquired a new stake in shares of IQVIA in the third quarter valued at approximately $57,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Performance

NYSE:IQV opened at $193.65 on Monday. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock’s 50-day simple moving average is $200.41 and its 200 day simple moving average is $218.02. The firm has a market capitalization of $35.15 billion, a PE ratio of 25.82, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.81 EPS for the current fiscal year.

Insider Activity at IQVIA

In other news, Director John G. Danhakl bought 1,275 shares of the company’s stock in a transaction on Tuesday, December 3rd. The stock was purchased at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the transaction, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 1.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

IQV has been the subject of several research reports. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. TD Cowen decreased their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. JPMorgan Chase & Co. reduced their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th. The Goldman Sachs Group lowered their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Robert W. Baird decreased their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $251.67.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.